Skip to main content

Table 4 Percentage of subjects for each treatment group reporting adverse events

From: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

Adverse event Quetiapine (%, n) Placebo (%, n)
Sedation 75% (15) 33.3%(7)
Dry mouth 15% (3) 0
Headache 15% (3) 38% (8)
Fatigue 15% (3) 19% (4)
Irritability 10% (2) 4.7% (1)
Impaired concentration 10% (2) 0
Dizziness 5% (1) 14.3% (3)
Nausea 5% (1) 9.5% (2)
Increased appetite 5% (1) 9.5% (2)
Delayed ejaculation 5% (1) 0
Weight gain 5% (1) 0
Worsening mood 5%(1) 4.7%(1)
Memory difficulties 5%(1) 0
Muscle aches 5%(1) 0
Abdominal tenderness 5%(1) 0
Slurred speech 5%(1) 0